{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lisanby SH"],"funding":["NIMH NIH HHS","National Institute of Mental Health"],"pagination":["15-28"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8595359"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(1)"],"pubmed_abstract":["<h4>Objective</h4>There is limited information regarding neurocognitive outcomes of right unilateral ultrabrief pulse width electroconvulsive therapy (RUL-UB ECT) combined with pharmacotherapy in older adults with major depressive disorder. We report longitudinal neurocognitive outcomes from Phase 2 of the Prolonging Remission in Depressed Elderly (PRIDE) study.<h4>Method</h4>After achieving remission with RUL-UB ECT and venlafaxine, older adults (≥60 years old) were randomized to receive symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium) or pharmacotherapy-only. A comprehensive neuropsychological battery was administered at baseline and throughout the 6-month treatment period. Statistical significance was defined as a p-value of less"],"journal":["The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry"],"pubmed_title":["Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study."],"pmcid":["PMC8595359"],"funding_grant_id":["U01 MH086127","U01 MH081362","U01 MH084241","U01 MH086122","U01 MH055495","U01 MH086123","U01 MH086130","U01 MH086120"],"pubmed_authors":["Briggs MC","Cullum CM","Geduldig ET","Kaliora S","Prudic J","Deng ZD","Rudorfer MV","Bailine SH","Kellner CH","Young RC","Tobias KG","Petrides G","Knapp RG","McCall WV","Bernhardt E","Sampson S","Liebman LS","Greenberg RM","Latoussakis V","Weiner RD","Lisanby SH","Teklehaimanot AA","McClintock SM","Husain MM","Mueller M","Rosenquist PB","Alexopoulos G","Prolonging Remission in Depressed Elderly (PRIDE) Work Group"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal Neurocognitive Effects of Combined Electroconvulsive Therapy (ECT) and Pharmacotherapy in Major Depressive Disorder in Older Adults: Phase 2 of the PRIDE Study.","description":"<h4>Objective</h4>There is limited information regarding neurocognitive outcomes of right unilateral ultrabrief pulse width electroconvulsive therapy (RUL-UB ECT) combined with pharmacotherapy in older adults with major depressive disorder. We report longitudinal neurocognitive outcomes from Phase 2 of the Prolonging Remission in Depressed Elderly (PRIDE) study.<h4>Method</h4>After achieving remission with RUL-UB ECT and venlafaxine, older adults (≥60 years old) were randomized to receive symptom-titrated, algorithm-based longitudinal ECT (STABLE) plus pharmacotherapy (venlafaxine and lithium) or pharmacotherapy-only. A comprehensive neuropsychological battery was administered at baseline and throughout the 6-month treatment period. Statistical significance was defined as a p-value of less","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-05-08T02:07:35.86Z","creation":"2025-02-18T22:34:19.442Z"},"accession":"S-EPMC8595359","cross_references":{"pubmed":["34074611"],"doi":["10.1016/j.jagp.2021.04.006"]}}